Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: Identifying B cell biomarkers for relapse to guide retreatment decisions

Annals of the Rheumatic Diseases

Volumn 74, Issue 9, 2015, Pages 1734-1738

  Md Yusof, Md Yuzaiful ^a,b   Vital, Edward M ^a,b   Das, Sudipto ^a,b   Dass, Shouvik ^a,b   Arumugakani, Gururaj ^a,b   Savic, Sinisa ^b   Rawstron, Andrew C ^b   Emery, Paul ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD19 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; RITUXIMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; FEMALE; IMMUNOLOGY; LYMPHOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; RETREATMENT;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES;

EID: 84942093274     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206496     Document Type: Article

References (20)

1. Md Yusof MY, Vital EM, Emery P. B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. Expert Rev Clin Immunol 2013;9:761-72.
2. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
3. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
4. Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011;63: 3038-47.
5. Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) 2011;50:2223-32.
6. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012;64:3770-8.
7. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2012;51:634-43.
8. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394-400.
9. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3760-9.
10. Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology (Oxford) 2013;52:2041-7.
11. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80.
12. Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010;62:1273-9.
13. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
14. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32.
15. Luqmani R. Maintenance of clinical remission in ANCA-associated vasculitis. Nat Rev Rheumatol 2013;9:127-32.
16. Dass S, Rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008;58:2993-9.
17. Thiel J, Salzer U, Hassler F, et al. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides. Autoimmunity 2013;46:429-38.
18. Cherukuri A, Rothstein DM, Clark B, et al. Immunologic human renal allograft injury associates with an altered IL-10/TNF-alpha expression ratio in regulatory B cells. J Am Soc Nephrol 2014;25:1575-85.
19. Wilde B, Thewissen M, Damoiseaux J, et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 2013;72:1416-19.
20. Todd SK, Pepper RJ, Draibe J, et al. Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2014;53:1693-703.